CEQUENT PHARMACEUTICALS

An early-stage biopharmaceutical company, Cequent is pioneering the development of novel therapeutics to prevent and treat a wide range of human diseases รขโฌโ from inflammatory diseases to cancer รขโฌโ based on the company's proprietary technology, TransKingdom RNA interference (tkRNAi). Cequent's first products, now in pre-clinical development, are drug candidates targeting colon-cancer prevention and inflammatory bowel disease. The company designed its powerful tkRNAi technology to deac... tivate specific disease-causing genes safely and effectively, using non-pathogenic bacteria as an engine to produce and deliver RNAi directly into cells. It is based on ground-breaking scientific research originating at the Institut Pasteur (Paris, France) and at the Beth Israel Deaconess Medical Center/Harvard Medical School. A privately held company based in Cambridge, Massachusetts, Cequent was established in 2006. In July 2010, Cequent Pharmaceuticals was acquired by Marina Biotech, Inc (formerly MDRNA, Inc) for $46M.
CEQUENT PHARMACEUTICALS
Industry:
Biotechnology Health Care Therapeutics
Founded:
2006-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.cequentpharma.com
Total Employee:
11+
Status:
Active
Contact:
617-995-7940
Email Addresses:
[email protected]
Total Funding:
12.4 M USD
Technology used in webpage:
SPF Domain Not Resolving OVH
Similar Organizations
Vigeo Therapeutics
Vigeo Therapeutics is a biopharmaceutical company developing novel therapeutic agents intended to treat advanced malignant tumors.
Current Employees Featured
Founder
Investors List
Novartis Venture Fund
Novartis Venture Fund investment in Series A - Cequent Pharmaceuticals
Nexus Medical Partners
Nexus Medical Partners investment in Series A - Cequent Pharmaceuticals
Ampersand Capital Partners
Ampersand Capital Partners investment in Series A - Cequent Pharmaceuticals
Pappas Ventures
Pappas Ventures investment in Series A - Cequent Pharmaceuticals
Official Site Inspections
http://www.cequentpharma.com
- Host name: ip79.ip-144-217-233.net
- IP address: 144.217.233.79
- Location: Beauharnois Canada
- Latitude: 45.3161
- Longitude: -73.8736
- Timezone: America/Toronto
- Postal: J6N

More informations about "Cequent Pharmaceuticals"
Cequent Pharmaceuticals - Prevent and Treat a Wide Range of โฆ
An early-stage biopharmaceutical company, Cequent is pioneering the development of novel therapeutics to prevent and treat a wide range of human diseases from inflammatory diseases โฆSee details»
Company | Cequent Pharma
About Cequent Pharmaceuticals, Inc. An early-stage biopharmaceutical company, Cequent is pioneering the development of novel therapeutics to prevent and treat a wide range of human โฆSee details»
Cequent Pharmaceuticals - Crunchbase Company โฆ
Contact Email [email protected] Phone Number 617-995-7940 An early-stage biopharmaceutical company, Cequent is pioneering the development of โฆSee details»
Board of Directors - Cequent Pharma
Joining Peter D. Parker on the Cequent Pharmaceuticals, Inc. Board of Directors are: Chiang J. Li, M.D. Founder, Director and Chairman of Scientific Advisory BoardSee details»
Cequent Pharmaceuticals Company Profile | Management and
Cequent Pharmaceuticals Profile and History . Cequent is pioneering the development of novel therapeutics to prevent and treat a wide range of human disorders -- from inflammatory โฆSee details»
Cequent Pharmaceutials Inc., Peter D. Parker,
[email protected]: Phone: 1-617-995-7940: Website: www.cequentpharma.com Fax: 1-617-995-7941: Summary ; Executive Details ; Board Members ; Business Information The โฆSee details»
Cequent Pharmaceuticals - Ownership and Business Overview
Www.cequentpharma.com. Profile Investors (2) Analytics Developer of therapies based on RNA interference (RNAi) Company Summary. SECTOR. Life Science. Established. 2003. Investor โฆSee details»
Cequent Pharmaceuticals, Inc. - Drug pipelines, Patents, Clinical ...
Explore Cequent Pharmaceuticals, Inc. with its drug pipeline, therapeutic area, technology platform, .See details»
Cequent Pharmaceuticals - PitchBook
Cequent Pharmaceuticals General Information Description. Developer of RNAi-based therapies based in Cambridge, Massachusetts. The company focuses on biopharmaceutical products based on RNA interference to prevent and treat a โฆSee details»
Cequent Pharmaceuticals - Products, Competitors, Financials, โฆ
May 18, 2016 Headquarters Location. One Kendall Square Building 700 First Floor. Cambridge, Massachusetts, 02139, United States. 617-995-7940See details»
Management Team - Cequent Pharma
Peter D. Parker President and CEO. Mr. Parker is President and CEO of Cequent Pharmaceuticals, Inc. Prior to joining Cequent, Mr. Parker was a General Partner at โฆSee details»
Cequent Pharmaceuticals Management Team | Org Chart
Get contact details including emails and phone numbers (business & personal).See details»
Peter Parker Cequent Pharmaceuticals Chief Executive Officer Profile
Www.cequentpharma.com: Company Description : Cequent Pharmaceuticals, Inc. is an early-stage biopharmaceutical company developing new clinically compatible therapies based on โฆSee details»
Cequent Pharmaceuticals. | (617) 995-7943 | Cambridge ... - AllBiz
Alison Silva is the primary contact at Cequent Pharmaceuticals.. You can contact Cequent Pharmaceuticals. by phone using number (617) 995-7943.See details»
Cequent Names Ted Hibben Chief Business Officer
Jan 12, 2009 Regarding Mr. Hibben's role at Cequent, Mr. Parker said, "Ted will focus on external partnering activities in three major areas. On our inflammatory bowel disease (IBD) โฆSee details»
Cequent Pharmaceuticals, Inc. Names F. Stephen Laroux, Ph.D
Jun 2, 2009 About Cequent Pharmaceuticals, Inc. (www.cequentpharma.com) An early-stage biopharmaceutical company, Cequent is pioneering the development of novel therapeutics to โฆSee details»
Our Partners | Cequent Pharma
The Novartis Institutes for BioMedical Research (NIBR) is Novartis global research organization. Informed by clinical insights from their translational medicine team, NIBR uses modern science โฆSee details»
Pamela Fekete Cequent Pharmaceuticals VP - Regulatory Affairs โฆ
Www.cequentpharma.com: Company Description : Cequent Pharmaceuticals, Inc. is an early-stage biopharmaceutical company developing new clinically compatible therapies based on โฆSee details»
Scientific Team - Cequent Pharma
Johannes Fruehauf, M.D. Vice President, Research Dr. Fruehauf is VP, Research at Cequent Pharmaceuticals, Inc. and co-inventor of transkingdom RNAi (tkRNAi).See details»
Clariant announces simplified organizational and leadership โฆ
Now is the right time to align the organization more closely to customers, businesses and markets. The new setup will further strengthen our position as a leader in sustainability and โฆSee details»